UNSPSC 51292005: Clorgiline

This classification denotes a monoamine oxidase inhibitor with the molecular formula C13H15Cl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LYJ16FZU9Q, chemically known as 2-propynylamine, n-(3-(2,4-dichlorophenoxy)propyl)-n-methyl- but generally known as clorgiline, which bears US NIH Compound Identifier 4380. European Medicines Agency schedules Clorgiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06755MIG.

UNSPSC 51292005 Clorgiline is a Commodity code that captures pharmaceutical products and related health-system supplies procured by state and local health agencies, though the recent opportunities tagged under it span a broader pharmaceutical-procurement landscape than the code name alone suggests. State and local governments are actively buying naloxone kits, drug deactivation systems, generic pharmaceuticals, and over-the-counter products through this classification. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which serves Oregon and other participating states). The work ranges from direct purchase orders for emergency-response medications to manufacturer-relationship building for pharmacy benefit programs and cooperative statewide or multi-state contracts for generic drug supply chains.

Activity is concentrated in Florida, Texas, and Minnesota as of mid-2026, with the MMCAP cooperative vehicle extending reach across multiple states including Oregon. Recent representative solicitations include Seminole County's July 2026 IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB due July 26, 2026, with quarterly deliveries to Sanford, Florida), the Texas HHS Commission's March 2026 RFI HHS0017013 seeking vendor information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements (RFI response deadline April 3, 2026), and MMCAP's January 2026 RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with proposals due March 26, 2026 and effective July 1, 2026. Contracts typically require cGMP and Drug Supply Chain Security Act compliance, E-Verify documentation, workers' compensation and commercial general liability insurance, and fixed or tiered pricing models.